Legend Biotech Corporatio... (LEGN)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Legend Biotech Corporation Statistics
Share Statistics
Legend Biotech Corporation has 183.45M shares outstanding. The number of shares has increased by 0.85% in one year.
Shares Outstanding | 183.45M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0.15% |
Owned by Institutions (%) | n/a |
Shares Floating | 181.93M |
Failed to Deliver (FTD) Shares | 671 |
FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 22.95M, so 12.51% of the outstanding shares have been sold short.
Short Interest | 22.95M |
Short % of Shares Out | 12.51% |
Short % of Float | 12.61% |
Short Ratio (days to cover) | 15.37 |
Valuation Ratios
The PE ratio is -20.44 and the forward PE ratio is -59.97.
PE Ratio | -20.44 |
Forward PE | -59.97 |
PS Ratio | 37.16 |
Forward PS | 4.5 |
PB Ratio | 8.47 |
P/FCF Ratio | -25.47 |
PEG Ratio | n/a |
Enterprise Valuation
Legend Biotech Corporation has an Enterprise Value (EV) of 9.65B.
EV / Earnings | -18.61 |
EV / Sales | 33.83 |
EV / EBITDA | -20.18 |
EV / EBIT | -21.95 |
EV / FCF | -23.19 |
Financial Position
The company has a current ratio of 6.92, with a Debt / Equity ratio of 0.26.
Current Ratio | 6.92 |
Quick Ratio | 6.83 |
Debt / Equity | 0.26 |
Total Debt / Capitalization | 20.8 |
Cash Flow / Debt | -1.2 |
Interest Coverage | -20.17 |
Financial Efficiency
Return on equity (ROE) is -0.41% and return on capital (ROIC) is -27.72%.
Return on Equity (ROE) | -0.41% |
Return on Assets (ROA) | -0.28% |
Return on Capital (ROIC) | -27.72% |
Revenue Per Employee | 118.81K |
Profits Per Employee | -215.94K |
Employee Count | 2.40K |
Asset Turnover | 0.15 |
Inventory Turnover | 7.42 |
Taxes
Income Tax | -1.86M |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -37.65% in the last 52 weeks. The beta is 0.11, so Legend Biotech Corporation's price volatility has been higher than the market average.
Beta | 0.11 |
52-Week Price Change | -37.65% |
50-Day Moving Average | 36.97 |
200-Day Moving Average | 45.89 |
Relative Strength Index (RSI) | 60.09 |
Average Volume (20 Days) | 1.47M |
Income Statement
In the last 12 months, Legend Biotech Corporation had revenue of 285.14M and earned -518.25M in profits. Earnings per share was -2.94.
Revenue | 285.14M |
Gross Profit | 140.93M |
Operating Income | -439.49M |
Net Income | -518.25M |
EBITDA | -477.87M |
EBIT | -439.49M |
Earnings Per Share (EPS) | -2.94 |
Balance Sheet
The company has 1.28B in cash and 328.67M in debt, giving a net cash position of 949.04M.
Cash & Cash Equivalents | 1.28B |
Total Debt | 328.67M |
Net Cash | 949.04M |
Retained Earnings | -1.48B |
Total Assets | 1.74B |
Working Capital | 1.08B |
Cash Flow
In the last 12 months, operating cash flow was -393.28M and capital expenditures -22.72M, giving a free cash flow of -416.00M.
Operating Cash Flow | -393.28M |
Capital Expenditures | -22.72M |
Free Cash Flow | -416.00M |
FCF Per Share | -2.36 |
Margins
Gross margin is 49.42%, with operating and profit margins of -154.13% and -181.75%.
Gross Margin | 49.42% |
Operating Margin | -154.13% |
Pretax Margin | -182.41% |
Profit Margin | -181.75% |
EBITDA Margin | -167.59% |
EBIT Margin | -154.13% |
FCF Margin | -145.89% |
Dividends & Yields
LEGN does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -7.85% |
FCF Yield | -6.05% |
Analyst Forecast
The average price target for LEGN is $84.5, which is 125.5% higher than the current price. The consensus rating is "Buy".
Price Target | $84.5 |
Price Target Difference | 125.5% |
Analyst Consensus | Buy |
Analyst Count | 13 |
Scores
Altman Z-Score | 4.87 |
Piotroski F-Score | 4 |